Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VDPHL01 in androgenetic alopecia
NCT06527365Phase 2Active, not recruiting
- Sponsor
- Veradermics
- Start
- Jul 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of VDPHL01 in androgenetic alopecia (AGA), sponsored by Veradermics. Primary endpoints: Total Area Hair Count (non-vellus) at 12 months and Subject Evaluation of Treatment Benefit at 12 months. Started Jul 2024; status: active, not recruiting.
02
Drugs
VDPHL01
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT06527365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06527365.